Giron L T, Koller W C
Neurology Service, Department of Veterans Affairs Medical Center, Kansas City, Missouri, USA. GIRON.LOUIS_T+@KANSAS-CITY.VA.GOV
Drug Saf. 1996 Jun;14(6):365-74. doi: 10.2165/00002018-199614060-00002.
Levodopa-induced dyskinesias result in considerable functional impairment for patients and formidable therapeutic challenges for physicians. A practical method of treating such dyskinesias is first to classify the levodopa dyskinesias according to their temporal profile after drug administration, namely, into predictable (interdose, biphasic and 'off-period') and unpredictable ('on-off') dyskinesias. Treatment of each type of dyskinesia requires a different and relatively specific therapeutic strategy. With progression of Parkinson's disease, the threshold for interdose dyskinesia lowers, while the threshold for antiparkinsonian efficacy is unchanged; therefore, the strategy is to maintain levodopa concentrations between these 2 thresholds and avoid high concentrations. Frequent small doses of liquid levodopa preparations may be indicated. Clozapine appears to increase the threshold for dyskinesia. However, its usefulness is limited primarily by dose-related sedation and by dose-unrelated agranulocytosis. Buspirone and fluoxetine may have specific antidyskinetic benefit. Surgical treatment may aid selected patients, although criteria for selection are not fully established. The biphasic dyskinesias occur just before and just after an oral dose of levodopa. They result when levodopa concentrations fall below or rise above the threshold for therapeutic efficacy; therefore, the strategy is to maintain concentrations as nearly constant as possible above that threshold. Dopamine agonists such as subcutaneous apomorphine combined with domperidone may be particularly helpful. Thalamic stimulation can also benefit selected patients. 'Off-period' dyskinesias occur at times of predicted low concentrations of levodopa. The treatment strategy is to provide sufficient levodopa or dopaminergic stimulation during those intervals. Dopamine agonists (e.g. bromocriptine at night) may help the characteristic early foot dystonia. Anticholinergic agents may also help. The unpredictable ('on-off') dyskinesias are first analysed to establish a pattern of response. Then, on the basis of that pattern, they are treated by maintaining levodopa concentrations or dopaminergic tone during the periods that would ordinarily be 'off.' Administration of liquid levodopa preparations, addition of dopaminergic agents, restriction of treatment during the morning hours as well as restriction of the majority of dietary protein in the evening meal may provide a period of predictable good function early in the day. Clozapine, even early in treatment, appears to reduce the incidence of these dyskinesias. Rescue with apomorphine during a malignant prolonged 'off' phase is particularly valuable.
左旋多巴诱发的运动障碍给患者带来了相当大的功能损害,也给医生带来了巨大的治疗挑战。治疗此类运动障碍的一种实用方法是首先根据给药后运动障碍出现的时间模式对左旋多巴诱发的运动障碍进行分类,即分为可预测的(剂间、双相和“关期”)和不可预测的(“开-关”)运动障碍。每种类型的运动障碍治疗都需要不同且相对特定的治疗策略。随着帕金森病的进展,剂间运动障碍的阈值降低,而抗帕金森病疗效的阈值不变;因此,策略是将左旋多巴浓度维持在这两个阈值之间,避免高浓度。可能需要频繁小剂量使用液体左旋多巴制剂。氯氮平似乎会提高运动障碍的阈值。然而,其效用主要受剂量相关的镇静作用和与剂量无关的粒细胞缺乏症的限制。丁螺环酮和氟西汀可能具有特定的抗运动障碍益处。手术治疗可能对部分患者有帮助,尽管选择标准尚未完全确立。双相运动障碍发生在口服左旋多巴剂量之前和之后。当左旋多巴浓度低于或高于治疗疗效阈值时就会出现这种情况;因此,策略是将浓度尽可能维持在该阈值以上并保持恒定。多巴胺激动剂,如皮下注射阿扑吗啡联合多潘立酮,可能会特别有帮助。丘脑刺激也可能使部分患者受益。“关期”运动障碍发生在预计左旋多巴浓度较低的时候。治疗策略是在这些时间段提供足够的左旋多巴或多巴胺能刺激。多巴胺激动剂(如夜间使用溴隐亭)可能有助于治疗典型的早期足部肌张力障碍。抗胆碱能药物也可能有帮助。对于不可预测的(“开-关”)运动障碍,首先要进行分析以确定反应模式。然后,根据该模式,在通常会“关”的时间段通过维持左旋多巴浓度或多巴胺能张力来进行治疗。服用液体左旋多巴制剂、添加多巴胺能药物、限制上午时段的治疗以及限制晚餐中大部分膳食蛋白质的摄入,可能会在一天早些时候提供一段可预测的良好功能期。氯氮平即使在治疗早期似乎也能降低这些运动障碍的发生率。在恶性延长的“关”期使用阿扑吗啡进行抢救特别有价值。